Table 1

Glycaemic control in people with type 2 diabetes prescribed two or more oral agents concurrently.

Number of types of oral agents prescribed	n	Pre-therapy HbA_1c^a Mean % (SD)	Post-therapy HbA_1c^b Mean % (SD)	Mean difference % Pre-HbA_1c – Post-HbA_1c (95% CI)	P-value	Number (%) with HbA_1c ≥7.5% post-therapy	Number (%) with HbA_1c ≥8.5% post-therapy
≥2	5064	9.07 (1.51)	8.16 (1.57)	0.91 (0.86 to 0.95)	<0.001	3153 (62.26)	1712 (33.81)

2	4174	9.04 (1.51)	8.04 (1.51)	1.00 (0.95 to 1.05)	<0.001	2468 (59.13)	1280 (30.67)

3	854	9.21 (1.49)	8.73 (1.72)	0.48 (0.37 to 0.59)	<0.001	658 (77.05)	411 (48.13)

4	36	9.16 (1.49)	9.34 (2.18)	−0.19 (−0.79 to 0.42)	0.54	27 (75.00)	21 (58.33)

Pre-2003	2713	9.22 (1.56)	8.28 (1.66)	0.93 (0.87 to 0.99)	<0.001	1755 (64.69)	1023 (37.71)

Post-2003	2351	8.90 (1.43)	8.02 (1.46)	0.87 (0.81 to 0.94)	<0.001	1398 (59.46)	689 (29.31)

↵a Pre-therapy HbA_1c (haemoglobin A_1c) is the last available HbA_1c assessment in the 6 months prior to initiation of a patient's last oral agent.
↵b Post-therapy HbA_1c is the last available HbA_1c assessment in the 6 months following initiation of their last oral agent.